Accueil   Diary - News   All news Focus on ImmunID

Focus on ImmunID

ImmunID Announces Rapid Enrolment of Patients in its PREDICT-ID Melanoma Clinical Trial for Prediction of Response to an Immunotherapy

Grenoble, France, January 21, 2015 — ImmunID, an immune molecular diagnostics company, announced today the enrolment of the first five patients in its PREDICT-ID Melanoma study to assess the predictive value of immune profiles for response to Ipilimumab®, an immunomodulatory agent.

One month after receiving authorization from the French regulatory bodies for the PREDICT-ID study, ImmunID is delighted to announce that the first two clinical centers, in Lyon and Angers, have recruited five metastatic melanoma patients. These two hospitals will be shortly followed by six additional renowned French c



Read the Press Release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree